Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04324840 · ClinicalTrials.gov registry record · Phase 1
A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 184
- Enrollment target
NCT04324840: Clinical Trial Phase 1 study, sponsored by Celgene.
NCT04324840 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 184 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (207% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04324840, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 184 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of CC-90010 when combined with standard of care treatment, temozolomide (TMZ) with or without radiotherapy (RT) in the newly diagnosed WHO Grade IV glioblastoma (ndGBM).
Primary Outcome
Parts A and B
Interventions
- DRUG Temozolomide
- RADIATION Radiotherapy
- DRUG CC-90010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2020-07-10 |
| Est. Completion | 2024-07-09 |
| Phase | Phase 1 |
Why NCT04324840 stopped before completion
NCT04324840 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (207% higher).
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT04324840 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04324840 about?
NCT04324840 is a clinical study titled "A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma". The purpose of this study is to determine the safety and tolerability of CC-90010 when combined with standard of care treatment, temozolomide (TMZ) with or without radiotherapy (RT) in the newly diagnosed WHO Grade IV glioblastoma (ndGBM).
What is the current status of trial NCT04324840?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 184 participants. The study started on 2020-07-10. Estimated completion is 2024-07-09.
What interventions are being tested in trial NCT04324840?
The interventions under investigation include: Temozolomide (DRUG), Radiotherapy (RADIATION), CC-90010 (DRUG).
Who is sponsoring clinical trial NCT04324840?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04324840's enrollment target sits among peer trials
184 294th of 2000 higher than 1,704 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI